HomeHealth ConditionsDiabetesGlucose uptake inhibitors: A new method to fight diabetes?

Glucose uptake inhibitors: A new method to fight diabetes?

Researchers investigated if SGLT-1, a rate-limiting protein in glucose metabolism, can provide clues to help fight diabetes.

Diabetes occurs when the body is unable to process sugar after a meal. It can lead to several health complications such as heart disease and kidney failure. About 7% of Canadians live with diabetes.

The standard treatment of diabetes include metformin, insulin injections, and careful diet monitoring. These factors can help regulate the amount of sugar in the bloodstream of diabetic patients to a relatively normal level. However, these methods require patients to be vigilant about their eating and injection habits. Researchers and clinicians are now working to find new diabetes treatments that will require less supervision to further improve patients’ quality of life.

What is SGLT-1?

SGLT-1 is a sodium/glucose transporter protein found in the small intestine. It is an essential protein that is the rate-limiting factor in sugar absorption from food into the bloodstream. Individuals born with a defective SGLT-1 gene have shown to have difficulties absorbing sugar, suffer from diarrhea and experience dehydration.

While SGLT-1 has been studied in healthy patients and patients with the defective gene, variants of SLGT-1 that are partially functional have not been closely studied. In a recent study published in the Journal of the American College of Cardiology, researchers investigate SGLT-1 variants to determine if partially functional SGLT-1 helps fight diabetes. Gene variants are slightly differing types of the same gene that occasionally provide beneficial or detrimental effects to people.

Researchers used whole-exome sequencing from patients in four populations within the Atherosclerosis Risk in Community cohort study to identify SGLT-1 gene variants. They examined 8478 patients and compared their SGLT-1 variant against blood glucose levels after a meal, glucose tolerance, and obesity. After analysis, 3 SGLT-1 variants were found that were associated with 25-27% lower impaired glucose tolerance, suggesting protection against diabetes.

SLGT-1 variants were associated with lower blood glucose levels

When the researchers examined these variants further, they found the three variants were associated with lower blood glucose levels after a meal, and lower obesity rates. These findings were found to be similar across Finnish and African-American populations.

Researchers examined the same patients after 25 years. They found that patients with the three identified SGLT-1 variants were associated with 27% lower risk of diabetes mellitus diagnosis, 20% lower risk of death.

These results suggest that SGLT-1 inhibition using pharmacological drugs may provide beneficial protection against diabetes. To test this theory, researchers conducted an analysis of SGLT-1 variants with blood glucose levels. The researchers found that a decrease of 20mg/dl of blood glucose facilitated by the SGLT-1 variants was associated with 57% lower risk of obesity, 42% lower risk of long-term diabetes, 47% lower risk of heart failure, and 34% lower risk of death.

Using SLGT-1 in drug development may help fight diabetes

Diabetes is a prevalent global disease that is associated with several health complications and a lower quality of life. Researchers investigating SGLT-1, a rate-limiting factor in glucose metabolism, found that individuals with certain SGLT-1 variants have a beneficial protection against diabetes due to lower glucose metabolism.

These variants lower the rate of glucose absorption from the small intestine into the bloodstream. It improves glucose tolerance from foods and lowers calorie consumption since not all the sugar in the gut is absorbed into the body. Researchers are optimistic that constructing SGLT-1 inhibitors to slightly impair its function may help fight diabetes.

Written by Aaron Kwong, MSc


  1. Seidelmann, S. B. et al. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. J. Am. Coll. Cardiol.72, 1763–1773 (2018).
  2. Diabetes, 2016. https://www150.statcan.gc.ca/n1/pub/82-625-x/2017001/article/54859-eng.htm. Statistics Canada (2017).


Please enter your comment!
Please enter your name here


Stay Connected

Article of the month

Prevalence of long COVID rises to nearly 7% of population

US government number crunchers published a briefing article in JAMA1, June 7, 2024, presenting the results of their latest round of analysis on long...

Joke Of The Day

-What's a difference between a general practitioner and a specialist? -One treats what you have the other thinks you have what he treats...


error: Content is read-only and copy-protected.